BioCentury | Aug 22, 2011
Emerging Company Profile

Tarsa: Fishing in a big pond

While the osteoporosis market is dominated by large companies with established or generic products, Tarsa Therapeutics Inc. believes it can carve out a niche as a second-line therapy for patients with mild to moderate disease....
BC Week In Review | Dec 22, 2008
Clinical News

Salmon-calcitonin nasal spray regulatory update

FDA granted tentative approval to an ANDA from MDRNA for generic calcitonin-salmon nasal spray to treat osteoporosis. Final approval is expected in June 2009 after the expiration of a 180-day exclusivity period from Apotex Inc....
BC Extra | Aug 26, 2005
Financial News

Nastech raises $23.3 million

Intranasal delivery company NSTK raised $23.3 million in a follow-on through the sale of 1.7 million shares at $13.50. The shares were sold from a shelf registration. The deal was underwritten by Needham; SunTrust Robinson...
BioCentury | Aug 8, 2005

Ebb & Flow

Just when it was beginning to look like the biotech financing window was nearing the end of its natural lifespan, an inflow of money into the sector is driving up the indices and fueling a...
BC Extra | Aug 5, 2005
Financial News

Nastech withdraws follow-on

Intranasal delivery company NSTK withdrew its proposed follow-on, citing market conditions. On Monday, the company proposed to sell 1.5 million shares, which would have raised $22.2 million if sold in full at NSTK's close of...
BC Extra | Aug 2, 2005
Financial News

Nastech proposes follow-on

Intranasal delivery company NSTK proposed to sell 1.5 million shares in a follow-on underwritten by Needham; SunTrust Robinson Humphrey; and Delafield Hambrecht. If sold at Monday's close of $14.78, NSTK would raise $22.2 million. The...
BC Week In Review | Nov 1, 2004
Company News

Nastech, Par Pharmaceutical deal

NSTK granted PRX exclusive U.S. rights to market and distribute a generic calcitonin-salmon nasal spray to treat osteoporosis. NSTK is responsible for obtaining approval of the compound, for which an ANDA was accepted for filing...
BC Week In Review | Feb 23, 2004
Clinical News

Nasal calcitonin-salmon spray regulatory update

FDA accepted for review an ANDA from NSTK for its calcitonin-salmon nasal spray to treat osteoporosis. NSTK said salmon calcitonin is 40-50 times more potent and has a longer duration of action than human calcitonin....
Items per page:
1 - 8 of 8